Cargando…
Screening and identification of an anti-PD-1 nanobody with antitumor activity
Blocking of programmed death protein 1 (PD-1) or its ligand PD-L1 with corresponding antibody to enhance T-cell response and mediate antitumor activity has been successfully applied in clinical practice. Several immune checkpoint inhibitors including monoclonal antibodies (mAbs) targeting PD-1 have...
Autores principales: | Zhang, Yanting, Yang, Shaoqi, Jiang, Dan, Li, Yanning, Ma, Shuo, Wang, Liyan, Li, Guangqi, Wang, Hongxia, Zhang, Aijun, Xu, Guangxian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867944/ https://www.ncbi.nlm.nih.gov/pubmed/36475449 http://dx.doi.org/10.1042/BSR20221546 |
Ejemplares similares
-
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021) -
Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018) -
Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2
por: Sun, Xin, et al.
Publicado: (2022) -
Establishment of a Colorectal Cancer-Related MicroRNA-mRNA Regulatory Network by Microarray and Bioinformatics
por: Jiang, Dan, et al.
Publicado: (2020) -
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)